At a glance
| Product | Lutathera |
|---|---|
| Role | Peptide receptor radionuclide therapy |
| Target | Somatostatin receptor-positive GEP-NETs |
| Age scope | 12 years and older |
| Route | Specialist intravenous infusion |
Overview
Lutathera treats gastroenteropancreatic neuroendocrine tumors in adults and children aged twelve and older when the tumors express somatostatin receptors. Patient selection depends on tumor biology, disease distribution, prior treatment and organ reserve. This is a radiopharmaceutical cancer treatment rather than a conventional hormone injection. Receptor imaging helps establish whether the target is present, while laboratory monitoring evaluates whether the patient can safely tolerate treatment. Its benefits concern tumor control in defined populations; the presence of a peptide component does not make it a general regenerative or longevity therapy.
How it works
The dotatate component binds somatostatin receptors, with greatest affinity for SSTR2, and is internalized by receptor-expressing cells. Lutetium-177 emits beta radiation that damages the targeted cell and nearby cells. The same targeting principle can be paired with a diagnostic isotope, but therapeutic radiation produces different exposure and toxicity. Normal receptor-expressing tissues and renal handling also contribute to treatment considerations.
Approved disease scope
The U.S. indication includes somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors of the foregut, midgut and hindgut. Eligibility is not established by a tumor name alone; receptor expression and clinical assessment guide selection.
Supporting sources [1]
Pivotal treatment evidence
NETTER-1 compared Lu-177 dotatate plus long-acting octreotide with high-dose octreotide in progressive midgut neuroendocrine tumors. It showed substantially improved progression-free survival. The controlled evidence supports tumor control and should not be presented as universal cure or guaranteed symptom relief.
Supporting sources [2]
Major treatment risks
Bone-marrow suppression, kidney toxicity and liver toxicity require monitoring. Delayed myelodysplastic syndrome and leukemia are recognized risks. Hypersensitivity and neuroendocrine hormonal crises can occur, and radiation can harm a fetus or affect fertility.
Supporting sources [1]
Why treatment requires specialist infrastructure
Amino-acid support, laboratory follow-up and radiation-protection procedures are part of the labeled treatment framework. Medical personnel and household contacts can be exposed to radiation from the patient or excreta, so institution-specific release and home-safety instructions matter.
Supporting sources [1]
A positive scan is not a complete treatment decision
Receptor-targeted imaging indicates where a radiolabeled peptide accumulates. It does not independently establish adequate marrow, kidney or liver reserve or determine the best place of radionuclide treatment among other oncology options.
Supporting sources [1]
Reading this profile
Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Lutetium-177 radiolabeled somatostatin analog.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- DailyMed: Lutathera prescribing information ↗Regulatory source · Checked 2026-10-27
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. ↗Original research · Checked 2026-10-27